{
  "docId": "019de077-2e43-774b-aad6-58a03a29d59d",
  "docSlug": "207557819f8810b573d3e2a3179a9bac",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 55 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 55,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The chart uses a bridge/waterfall structure to show revenue growth drivers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2e43-774b-aad6-58a03a29d59d/49",
  "deckHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d",
  "deckJsonHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d.json",
  "deckAnchorHref": "/decks/019de077-2e43-774b-aad6-58a03a29d59d#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.65,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Waterfall chart showing 2023 revenue, IRA/LOE impact, existing portfolio, new launches, and 2030 ambition.",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20a861e0-99cf-4062-bdb3-10a22d1e13f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.72,
        "y": 0.25
      },
      "kind": "list",
      "text": "Sustained leadership in disruptive categories; Broad portfolio with unique combination potential; Global, differentiated commercial model; Multiple blockbuster medicines.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb8a7fb7-318c-45bb-898b-830b9ebd9c98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. includes select medicines and pipeline opportunities. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Merck & Co., Inc. (Lynparza); Compugen (rilvegostomig).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82d566bf-bb6f-464f-8ae8-bd23417019e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca – ambition in oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e370527-e005-4973-a982-07266d4e5720",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "707f1c51-1561-455d-9af3-e15b1cfdac0d",
      "evidence": "chart/waterfall-bridge: Waterfall chart showing 2023 revenue, IRA/LOE impact, existing portfolio, new launches, and 2030 ambition.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "waterfall-bridge",
      "slug": null,
      "matchId": "e7c508e8-3b27-4173-9485-d39684333cc3",
      "evidence": "The slide uses a bridge chart to explain the delta between 2023 and 2030 revenue.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}